Niche pharma empire-building Cinven clinches Amdipharm and Mercury deals for £832m
This article was originally published in Scrip
Executive Summary
The European private equity firm Cinven has acquired family-owned niche pharmaceuticals company Amdipharm of the UK for £367 million, and is planning to merge it with Mercury Pharma (formerly Goldshield Group), which it bought for £465 million last month. The two companies' combined revenues are around £250 million, and EBITA is £100 million.